STP 206
Alternative Names: STP206Latest Information Update: 04 Feb 2019
At a glance
- Originator Sigma-Tau Pharmaceuticals
- Developer Leadiant Biosciences
- Class Anti-infectives; Bacteria; Probiotics
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Necrotising enterocolitis
Most Recent Events
- 05 Sep 2018 Leadiant Biosciences completes a phase Ib/IIa trial for Necrotising enterocolitis (Prevention) in USA (NCT01954017)
- 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
- 19 Oct 2015 STP 206 is still in phase II trials for Necrotising enterocolitis (Prevention) in USA